Common Contracts
7 similar Employment Agreement contracts by Tyra Biosciences, Inc.
TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Piyush Patel (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Daniel Bensen (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Ronald Swanson (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Hiroomi Tada (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Esther van den Boom (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Robert Hudkins (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
